SAN FRANCISCO, June 6, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
InvestorsJennifer Ruddock of Nektar Therapeutics415-482-5585
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-to-webcast-presentation-at-jefferies-2017-global-healthcare-conference-in-new-york-city-300469746.html
SOURCE Nektar Therapeutics
Subscribe to our Free Newsletters!
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...View All